Bill Overview
- Bill: S 4238
- Session: 222 (New Jersey)
- Title: End-Stage Kidney Disease Prevention and Innovation Act
- Purpose: Establish a formal program to study, prevent, and innovate treatments for rare kidney diseases, with an emphasis on end-stage kidney disease (ESKD) and disparities affecting minority and underserved communities. Includes a $10 million appropriation and a five-year authorization.
Main Goals and Intent
- Create Centers on Rare Kidney Disease Research within the Department of Health (DOH) to advance research, awareness, training, and clinical resources related to rare kidney diseases, including glomerular diseases.
- Improve understanding and management of rare kidney diseases to slow progression to ESKD, delay or reduce dialysis/transplant needs, and address disparities in access and outcomes.
Key Provisions
1) Establishment of Centers on Rare Kidney Disease Research
- DOH shall establish Centers on Rare Kidney Disease Research.
- The Commissioner of Health may enter into cooperative agreements and grant public or private nonprofit entities to plan, establish, strengthen, and fund basic operating support for the centers.
- An advisory board shall be created, including nephrologists, patient advocates, academic researchers, and public health experts.
2) Purposes and Activities of the Centers
The centers shall:
- Conduct research on causes, etiology, symptoms, diagnosis, progression, and treatment of rare kidney diseases (including glomerular diseases).
- Increase public awareness, especially in rural and underserved communities.
- Develop resources for clinical research, training, and demonstrations of diagnostic, prevention, control, and treatment methods.
- Award fellowships (potentially with stipends) for postgraduate nephrology training, focusing on:
- Prevention, diagnosis, and treatment for populations disproportionately affected (e.g., APOL1 gene considerations).
- Improving care quality for minorities and increasing the number of nephrologists serving these populations.
- Conduct experiments to evaluate treatment methods, with emphasis on delaying or eliminating dialysis and transplantation.
- Study methods to increase public awareness of rare kidney disease.
3) Targeted Use of Grants and Cooperative Agreements
- The DOH shall partner with at least one entity capable of serving disproportionately impacted minority and underserved communities, prioritizing in-State nonprofit hospitals, medical schools, and research institutions.
- Authorized uses of funds include:
- Covering patient care costs needed to conduct research.
- Clinical training and continuing education for health professionals on rare kidney diseases.
- Developing informational pamphlets for the public.
- Public education outreach, especially to rural and underserved communities.
- Education on renal diet, genetic testing, urinalysis programs, and mental health resources for families.
4) Research Standards and Protections
- Research funded under this section must study genotype-phenotype relationships in disease progression.
- Research shall not use quality-adjusted life years (QALYs), disability-adjusted life years (DALYs), or similar metrics that discriminate against individuals with disabilities in value/cost assessments.
5) Competitive Application Process
- DOH shall establish a competitive process to award grants, with objective criteria reflecting nephrology expertise, research capacity, reach to underserved populations, and institutional readiness.
6) Separate DOH Study on Rare Kidney Disease
- DOH must conduct a study on testing, prevention, precision medicine, and treatment for rare kidney disease, addressing:
- Impact of routine urinalysis on timely diagnosis and post-diagnosis care quality.
- Quality and reliability of kidney biopsy in diagnosis.
- Utility and use of genetic/genomic tests (including APOL1) and barriers to such testing (insurance coverage, access to counselors, etc.).
- Strategies to increase urinalysis/use of diagnostic testing and improve access to genetic testing.
- Social, behavioral, and biological factors contributing to disease.
- Treatment patterns under Medicare, Medicaid, and private insurance for disproportionately affected populations.
- Access to nephrologists for affected populations.
- Efforts to slow progression to ESKD in these populations.
- Patient trust in treating providers.
7) Reporting Requirement
- Within 12 months after expiration of the act, DOH must prepare a final report with findings and recommendations to the Governor and the Legislature, following applicable reporting statutes. Stakeholder consultation is required.
8) Appropriation and Duration
- General Fund appropriation not to exceed $10,000,000, with actual funding determined by the Commissioner of Health.
- Effective date: immediate upon enactment.
- Sunsets five years after enactment.
Affected Parties and Impacts
- State: Department of Health (DOH) and the Governor/Legislature (through reporting).
- Health care providers: Nephrologists, clinicians, and public health professionals involved in rare kidney disease research, prevention, and care.
- Institutions: In-State nonprofit hospitals, medical schools, and research institutions that partner as grant recipients or cooperative agreement partners.
- Patients and communities: Particularly racial/ethnic minorities and rural/underserved populations that experience disproportionate burden of rare kidney diseases and progression to ESKD.
- Public and patient advocates: Involvement via advisory board and outreach activities.
Procedural and Timeline Highlights
- Establishment of Centers and advisory board upon enactment.
- Competitive grant application process to award funding for centers.
- DOH study on testing and treatment to be conducted during the act’s term.
- A final comprehensive report due within 12 months after expiration (i.e., within one year after the five-year term ends).
- Five-year duration, with the act taking effect immediately at enactment.
Summary
S 4238 creates a dedicated framework within New Jersey’s Department of Health to combat rare kidney diseases and slow progression to end-stage kidney disease. It authorizes the creation of Centers on Rare Kidney Disease Research, funded through public-private partnerships and grants, and requires a mixed program of research, clinical education, public outreach, and patient support. The bill emphasizes equity, mandating outreach to minority and underserved populations, and prohibits the use of certain health outcome metrics (QALYs/DALYs) that disadvantage individuals with disabilities in its research. A state-initiated study will examine diagnostics, genetic testing (including APOL1), and care patterns, with a required comprehensive final report after the five-year period. The total cap for the program is $10 million, and the act expires five years after enactment.
